Skip to main content

Advertisement

SpringerLink
Log in

A nomogram based on 4-lncRNAs signature for improving prognostic prediction of hepatocellular carcinoma

  • RESEARCH ARTICLE
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

Long noncoding RNAs (lncRNAs) with abnormal expression are frequently seen in hepatocellular cancer patients (HCC). Previous studies have reported the correlation between lncRNA and prognosis processes of HCC patients. In this research, a graphical nomogram with lncRNAs signatures, T, M phases was developed using the rms R package to estimate the survival rates of HCC patients in year 1, 3, and 5.

Methods

To find the prognostic lncRNA and create the lncRNA signatures, univariate Cox survival analysis and multivariate Cox regression analysis were chosen. The rms R software package was used to build a graphical nomogram based on lncRNAs signatures to predict the survival rates in of HCC patients in 1, 3, and 5 years. Using “edgeR”, “DEseq” R packages to find the differentially expressed genes (DEGs).

Results

Firstly, a total of 5581 DEGs including 1526 lncRNAs and 3109 mRNAs were identified through bioinformatic analysis, of which 4 lncRNAs (LINC00578, RP11-298O21.2, RP11-383H13.1, RP11-440G9.1) were identified to be strongly related to the prognosis of liver cancer (P < 0.05). Moreover, we constructed a 4-lncRNAs signature by using the calculated regression coefficient. 4-lncRNAs signature is identified to significantly correlated with clinical and pathological characteristics (such as T stage, and death status of HCC patients).

Conclusions

A prognostic nomogram on the base of 4-lncRNAs markers was built, which is capable to accurately predict the 1-year, 3-year, and 5-year survival of HCC patients after the construction of the 4-lncRNAs signature linked with prognosis of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Global Burden of Disease Liver Cancer C, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–91.

    Article  PubMed  PubMed Central  Google Scholar 

  2. European Association for the Study of the Liver. Electronic address EEE and European Association for the Study of the L EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.

    Article  Google Scholar 

  3. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):448–58.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Dhanasekaran R, Bandoh S, Roberts LR. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Research. 2016;5:879.

    Article  Google Scholar 

  5. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.

    Article  PubMed  Google Scholar 

  6. Brown ZJ, Greten TF, Heinrich B. Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy. Hepatology. 2019;70(4):1437–42.

    Article  PubMed  Google Scholar 

  7. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Qian X, Zhao J, Yeung PY, Zhang QC, Kwok CK. Revealing lncRNA structures and interactions by sequencing-based approaches. Trends Biochem Sci. 2019;44(1):33–52.

    Article  CAS  PubMed  Google Scholar 

  9. Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018;109(7):2093–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Charles Richard JL, Eichhorn PJA. Platforms for investigating LncRNA functions. SLAS Technol. 2018;23(6):493–506.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Lai Q, Spoletini G, Mennini G, Laureiro ZL, Tsilimigras DI, Pawlik TM, et al. Prognostic role of artificial intelligence among patients with hepatocellular cancer: a systematic review. World J Gastroenterol. 2020;26(42):6679–88.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut. 2019;68(6):1065–75.

    Article  PubMed  Google Scholar 

  13. Fu Q, Yang F, Xiang T, Huai G, Yang X, Wei L, et al. A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy. Sci Rep. 2018;8(1):7933.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Klingenberg M, Matsuda A, Diederichs S, Patel T. Non-coding RNA in hepatocellular carcinoma: mechanisms, biomarkers and therapeutic targets. J Hepatol. 2017;67(3):603–18.

    Article  CAS  PubMed  Google Scholar 

  15. Zhang B, Li C, Sun Z. Long non-coding RNA LINC00346, LINC00578, LINC00673, LINC00671, LINC00261, and SNHG9 are novel prognostic markers for pancreatic cancer. Am J Transl Res. 2018;10(8):2648–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Gao Q, Wang ZC, Duan M, Lin YH, Zhou XY, Worthley DL, et al. Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents. Gastroenterology. 2017;152(1):232-242.e4.

    Article  CAS  PubMed  Google Scholar 

  17. Munir R, Lisec J, Swinnen JV, Zaidi N. Lipid metabolism in cancer cells under metabolic stress. Br J Cancer. 2019;120(12):1090–8.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lin Z, Lu D, Wei X, Wang J, Xu X. Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors. Am J Cancer Res. 2020;10(4):1085–102.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Li M, Hu J, Jin R, Cheng H, Chen H, Li L, et al. Effects of LRP1B regulated by HSF1 on lipid metabolism in hepatocellular carcinoma. J Hepatocell Carcinoma. 2020;7:361–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567(7747):257–61.

    Article  CAS  PubMed  Google Scholar 

  21. Sharpton SR, Schnabl B, Knight R, Loomba R. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease. Cell Metab. 2021;33(1):21–32.

    Article  CAS  PubMed  Google Scholar 

  22. Nam SH, Bae MR, Roh JL, Gong G, Cho KJ, Choi SH, et al. A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma. Oral Oncol. 2018;87:158–64.

    Article  PubMed  Google Scholar 

  23. Tellapuri S, Sutphin PD, Beg MS, Singal AG, Kalva SP. Staging systems of hepatocellular carcinoma: a review. Indian J Gastroenterol. 2018;37(6):481–91.

    Article  PubMed  Google Scholar 

  24. Bednarsch J, Czigany Z, Heise D, Joechle K, Luedde T, Heij L, et al. Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems. Langenbecks Arch Surg. 2021;406(1):75–86.

    Article  PubMed  Google Scholar 

  25. Zhu X, Tian X, Yu C, Shen C, Yan T, Hong J, et al. A long non-coding RNA signature to improve prognosis prediction of gastric cancer. Mol Cancer. 2016;15(1):60.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Song P, Jiang B, Liu Z, Ding J, Liu S, Guan W. A three-lncRNA expression signature associated with the prognosis of gastric cancer patients. Cancer Med. 2017;6(6):1154–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Zheng S, Zheng D, Dong C, Jiang J, Xie J, Sun Y, et al. Development of a novel prognostic signature of long non-coding RNAs in lung adenocarcinoma. J Cancer Res Clin Oncol. 2017;143(9):1649–57.

    Article  CAS  PubMed  Google Scholar 

  28. Sui J, Yang S, Liu T, Wu W, Xu S, Yin L, et al. Molecular characterization of lung adenocarcinoma: a potential four-long noncoding RNA prognostic signature. J Cell Biochem. 2019;120(1):705–14.

    Article  CAS  PubMed  Google Scholar 

  29. Huang GW, Xue YJ, Wu ZY, Xu XE, Wu JY, Cao HH, et al. A three-lncRNA signature predicts overall survival and disease-free survival in patients with esophageal squamous cell carcinoma. BMC Cancer. 2018;18(1):147.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Mahpour A, Mullen AC. Our emerging understanding of the roles of long non-coding RNAs in normal liver function, disease, and malignancy. JHEP Rep. 2020;3(1): 100177.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Zhao QJ, Zhang J, Xu L, Liu FF. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma. World J Gastroenterol. 2018;24(30):3426–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Yan J, Zhou C, Guo K, Li Q, Wang Z. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma. J Cell Biochem. 2019;120(1):213–23.

    Article  CAS  PubMed  Google Scholar 

  34. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–80.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was supported by Social Development Mandatory Program of Qiqihar Science and Technology Bureau (No.SFGG-201951).

Author information

Author notes

  1. Qingguo Mo and Wenjing Li contributed equally to this work.

Authors and Affiliations

  1. Department of Interventional Radiology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China

    Qingguo Mo, Lin Liu & Zhidong Hao

  2. School of Pharmacy, Qiqihar Medical University, Qiqihar, China

    Wenjing Li

  3. The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, China

    Shengjun Jia

  4. Department of Vascular Burn Surgery, The Third Affiliated Hospital of Qiqihar Medical University, Tiefeng District, 27 Tai Shun Street, Qiqihar, 161000, Heilongjiang Province, China

    Yongsheng Duo

Authors
  1. Qingguo Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wenjing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhidong Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shengjun Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yongsheng Duo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

QM and YD: are responsible for the conception or design of the work. WL, LL, ZH and SJ: contribute the acquisition, analysis, or interpretation of data for the work. All authors finally approved the manuscript version to be published. YD is the guarantor of the article.

Corresponding author

Correspondence to Yongsheng Duo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by Ethical Committee of The Third Affiliated Hospital of Qiqihar Medical University and conducted in accordance with the ethical standards. (Approval number: 2018LL-11). All experiments were performed complying with the relevant regulations (Supplementary Table 2).

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Informed consent

Subjects signed the informed consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

12094_2023_3244_MOESM1_ESM.pdf

Supplementary Supplementary Figure 1. Survival status along with survival times of training group (a-d), testing group (e-h). file1 (PDF 301 KB)

12094_2023_3244_MOESM2_ESM.pdf

Supplementary Supplementary Figure 2. Clustering analysis of key prognostic lncRNAs by using different cut-of values file2 (PDF 115 KB)

Supplementary file3 (PDF 1355 KB)

Supplementary Supplementary Figure 3. Verification chart of IC50 linear model for antitumor drugs. file4 (DOCX 156 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mo, Q., Li, W., Liu, L. et al. A nomogram based on 4-lncRNAs signature for improving prognostic prediction of hepatocellular carcinoma. Clin Transl Oncol 26, 375–388 (2024). https://doi.org/10.1007/s12094-023-03244-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-023-03244-z

Keywords

Search

Navigation